Conference Programme
Disrupting Bio Innovation
9 July 2026
Our Programme
Keynote Presentations & Panel Discussions
Enjoy a day of Keynote Presentations and Panel discussions, plus the Exhibition Area and networking opportunities.
In an era defined by rapid technological developments, Disrupting Bio Innovation refers to the new technologies, policies and business models that are shaping the drug discovery and development landscape. Don’t miss this opportunity to join the One Nucleus network to engage with the pioneers driving the next wave of disruptive innovation and stay at the forefront of emerging trends.
Registration
Opening Remarks
Opening Keynote
Cathy Tralau-Stewart, Milner Therapeutics Institute
Scientific Breakthroughs Disrupting Bio Innovation
This session will focus on advances in molecular biology and bioengineering that are unlocking the next generation of therapeutics with a focus on the post-Covid momentum of mRNA therapeutics, and the delivery technologies enabling safer and more flexible approaches.
- 09:40 – 10:00 – 2 COMPANY CASE STUDIES
- Company Case Study 1 – Rose Hughes, Cartesian Therapeutics
- Company Case Study 2 – George Thom, AstraZeneca
- 10:00 – 10:40 – PANEL DISCUSSION
- Moderator: Victoria English, EverNow Publishing
- Panellists: Rose Hughes, Cartesian Therapeutics, George Thom, AstraZeneca, Jon Moore, Epitopea
Morning Coffee and Networking Break
Disruptive Therapeutic Discovery Platform Technologies
Have computational tools and software platforms reached an inflection point in drug discovery? This session will examine how data centric platforms are advancing therapeutic development to help researches tackle complex biological questions.
- 11:10 – 11:30 – KEYNOTE PRESENTATION
Nicole Mather, Wellcome Genome Campus
- 11:30 – 11:50 – 2 COMPANY CASE STUDIES
- Company Case Study 1 – Karolina Makovskytė, Vugene
- 11:50 – 12:30 – PANEL DISCUSSION
- Moderator: Stephen Adams, Optimum Strategic Communications
- Panellists: Nicole Mather, Wellcome Genome Campus, Karolina Makovskytė , Vugene
Lunch and Networking
Disrupting Regulatory and Clinical Pathways
This session will explore approaches that are challenging traditional regulatory and clinical processes, with the reduction of animal models serving as a key example.
- 13:30 – 13:50 –KEYNOTE PRESENTATION
- 13:50 – 14:10 – 2 COMPANY CASE STUDIES
- Company Case Study 1 – Tomasz Kostrzewski, CN Bio
- Company Case Study 2 – Hannah Amies, Luvida
- 14:10 – 15:00 – PANEL DISCUSSION
- Panellists: Leona Fitzgerald, PPD™ clinical research business of Thermo Fisher Scientific, Tomasz Kostrzewski, CN Bio, Hannah Amies, Luvida
Afternoon Coffee and Networking Break
Disruptive Business Models for Translational Research
Exploring global operational models enabling biotech to scale more capital efficiently and competitively, the stakeholders involved, and growing importance of international regions like China.
- 15:30 – 16:10 – KEY LEARNINGS FROM THE BOSTON BOOTCAMP 2026
- Moderator: Nick Blevins, Knight Frank
- Panellists: Jenny Barnett, Monument Therapeutics, Benedict Cross, Stick Therapeutics, Darren Fergus, Profionics
- 16:10 – 16:30 – KEYNOTE PRESENTATION
- 16:30 – 17:10 – PANEL DISCUSSION – FLEXING A GLOBAL INNOVATION ECOSYSTEM
- Moderator: Mike Ward
- Panellists: Claire Thompson, Agility Life Sciences, Julian Gough, OutSee
Closing Remarks
Tony Jones, One Nucleus
Networking Drinks Reception
End
Programme is subject to change